Open AccessMolecular targeted therapies for pediatric atypical teratoid/rhabdoid tumors
Author(s) -
Zhang Chang,
Li Hao
Publication year - 2022
Publication title -
pediatric investigation
Language(s) - English
Resource type - Journals
ISSN - 2574-2272
DOI - 10.1002/ped4.12325
Subject(s) - atypical teratoid rhabdoid tumor , epigenetics , smarca4 , smarcb1 , medicine , targeted therapy , carcinogenesis , bioinformatics , radiation therapy , oncology , central nervous system , biology , cancer , genetics , gene , chromatin remodeling
Atypical teratoid/rhabdoid tumors (AT/RTs) are lethal central nervous system tumors, which are primarily diagnosed in infants. Current treatments for AT/RTs include surgery, radiotherapy, and chemotherapy; these treatments have poor prognoses and challenging side effects. The pivotal genetic event in AT/RT pathogenesis comprises the inactivation of SMARCB1 or SMARCA4 . Recent epigenetic studies have demonstrated mutual and subtype‐specific epigenetic derangements that drive tumorigenesis; the exploitation of these potential targets might improve the dismal treatment outcomes of AT/RTs. This review aims to summarize the literature concerning targeted molecular therapies for pediatric AT/RTs.